Clinical Assessment and Diagnosis in Oncology
What this domain tests
This domain covers the front end of the patient pathway: focused history and examination, objective documentation of performance status, evidence-based selection of laboratory and imaging tests, and histological confirmation with staging. Questions test whether your diagnostic sequence would survive an MDT review - not whether you can list every tumour marker.
Core rules
- Performance status is a prescription. Record ECOG (0 fully active; 1 restricted in strenuous activity but ambulatory and able to do light work; 2 up more than 50% of waking hours, self-caring, unable to work; 3 bed or chair more than 50%, limited self-care; 4 completely disabled). It predicts chemotherapy tolerance and trial eligibility more reliably than chronological age.
- Tissue diagnosis before treatment, except in defined emergencies (impending cord compression, SVC obstruction, airway compromise) or when a validated imaging-plus-biomarker diagnosis exists (e.g., HCC in cirrhosis meeting LI-RADS criteria).
- Stage with UICC/AJCC TNM, 8th edition, which for several tumours now incorporates grade, biomarkers or gene signatures (breast anatomical versus prognostic stage; HPV status in oropharyngeal cancer).
- Send targeted bloods: FBC, renal and liver function, calcium, LDH. Tumour markers only where they change management (AFP and beta-hCG in germ cell tumours, calcitonin in medullary thyroid cancer) - never as a screening test.
- Red flags - unintentional weight loss over 5% in six months, night pain, haemoptysis, new neurological deficit, hypercalcaemia - mandate urgent investigation.
Worked example
A 62-year-old smoker has a 4.0 cm right upper-lobe mass with ipsilateral hilar nodes; PET-CT shows no distant disease and biopsy confirms adenocarcinoma. T descriptor: 4.0 cm = T2a (3.1–4 cm); hilar nodes = N1; no metastases = M0. T2a N1 M0 maps to stage IIB in the 8th edition. Reasoning: the size boundary matters (3 cm or less is T1), and hilar nodes are ipsilateral intrapulmonary/peribronchial rather than mediastinal. Stage IIB supports adjuvant platinum doublet after resection; mislabelling it IIIA would wrongly add thoracic radiotherapy.
Traps
Using CEA or CA19-9 to 'exclude' malignancy; assigning stage before histology returns; confusing Karnofsky 70% with ECOG 3; forgetting that ECOG 3–4 usually contraindicates aggressive cytotoxic chemotherapy but not necessarily targeted agents or best supportive care.